Are Atypical Pathogens Important for Patients with Community-Acquired Pneumonia?

  • M. S. Niederman


The term “atypical pathogens” refers to a variety of organisms, including Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp., that can cause community-acquired pneumonia (CAP). This designation was developed when investigators realized that some patients with pneumonia had a clinical picture and natural history that differed from that seen in patients with pneumococcal infection. The syndrome, initially associated with M. pneumoniae [1], is characterized by gradual onset of illness, with low-grade fever, mucoid sputum and a non-toxic presentation, with a chest radiograph that shows more severe involvement than indicated by the patient’s findings. Over the years, the frequency of pneumonia due to atypical pathogens has been widely variable in clinical series, the need for therapy of these pathogens has been questioned, the role of these organisms in severe ICU-treated CAP has been controversial, and the definition of the patient most at risk has been uncertain. In addition, there has been debate about whether identifying the presence of the “atypical pneumonia syndrome” has any diagnostic value and whether clinicians should use the presence or absence of this syndrome to guide initial empiric antibiotic therapy of CAP [2–4].


Mixed Infection American Thoracic Society Pneumococcal Pneumonia Pneumococcal Infection Comorbid Illness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chanock RM, Hayflick L, Barile MF (1961) Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO. Proc Natl Acad Sci USA 478: 41Google Scholar
  2. 2.
    Woodhead MA, MacFarlane JT (1987) Comparative clinical laboratory features on legionella with pneumococcal and mycoplasma pneumonias. Br J Dis Chest 81: 133–139PubMedCrossRefGoogle Scholar
  3. 3.
    Farr BM, Kaiser DL, Harrison BDW, Connolly CK (1989) Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. Thorax 44: 1031–1035PubMedCrossRefGoogle Scholar
  4. 4.
    Niederman MS, Bass JB, Campbell GD, Fein AM, Grossman RF, Mandell LA, Marrie TJ, Sarosi GA, Torres A, Yu VL (1993) Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 148: 1418–1426PubMedGoogle Scholar
  5. 5.
    Sopena N, Sabria-Leal M, Pedro-Botet ML, Padilla E, Dominguez J, Morera J, Tudela P (1998) Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest 113: 1195–1200PubMedCrossRefGoogle Scholar
  6. 6.
    Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E et al (1995) Community-acquired pneumonia: impact of immune status. Am J Respir Crit Care Med 152: 1309–1315PubMedGoogle Scholar
  7. 7.
    Mundy LM, Oldach D, Autwaerter PG, Gaydos CA, Moore RD, Bartlett JG et al (1998) Implication for macrolide treatment in community-acquired pneumonia. Chest 113: 1201–1206PubMedCrossRefGoogle Scholar
  8. 8.
    Lieberman D, Schlaeffer F, Boldur I, Lieberman D, Horowith S, Friedman MG et al (1996) Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51: 179–184PubMedCrossRefGoogle Scholar
  9. 9.
    Marston BJ, Plouffe JF, File TM, Hackman BA, Salstrom SJ, Lipman HB et al (1997) Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 157: 1709–1718PubMedCrossRefGoogle Scholar
  10. 10.
    Steinhoff D, Lode H, Ruckdeschel G, Heidrich B, Rolfs A, Fehrenbach FJ, Mauch H, Hoffken G, Wagner J (1996) Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 22: 958–964PubMedCrossRefGoogle Scholar
  11. 11.
    Troy CJ, Peeling RW, Ellis AG et al (1997) Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. JAMA 277: 1214–1218PubMedCrossRefGoogle Scholar
  12. 12.
    Marrie TJ, Peeling RW, Fine MJ et al (1996) Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 101: 509–515CrossRefGoogle Scholar
  13. 13.
    Kauppinen MT, Saikku P, Kujala P, Herva E, Syrjala H (1996) Clinical picture of Chlamydia pneumoniae requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 51: 185–189PubMedCrossRefGoogle Scholar
  14. 14.
    Gordon GS, Throop D, Berberian L, Niederman M, Bass J, Alemayehu D, Mellis S (1996) Validation of the therapeutic recommendations of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients. Chest 110: 55S jGoogle Scholar
  15. 15.
    Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R et al (1997) Medical outcomes and antimicrobial costs with the use of the American Thoracic Society Guidelines for outpatients with community-acquired pneumonia. JAMA 278: 32–39PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1999

Authors and Affiliations

  • M. S. Niederman

There are no affiliations available

Personalised recommendations